Physician profile
Kevin Heath
NPI 1992702336
$8,231.75
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $787 · 2021: $1,856 · 2022: $1,877 · 2023: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.29 | 2019-2023 | |
| Janssen Biotech, INC. | $987.20 | 2019-2023 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $951.63 | 2019-2023 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $887.88 | 2019-2023 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $668.08 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $368.07 | 2022-2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $295.64 | 2021-2023 | |
| Celgene Corporation | $263.96 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $234.23 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $227.53 | 2019-2023 | Ocaliva |
| Organon LLC | $135.58 | 2022-2023 | Renflexis, Hadlima |
| Amgen INC. | $127.67 | 2021-2023 | Amjevita, Avsola |
| Gilead Sciences, INC. | $92.13 | 2019-2021 | |
| Ucb, INC. | $83.64 | 2019-2020 | |
| Braintree Laboratories, INC. | $80.29 | 2019-2023 | Sutab |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $73.24 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $60.23 | 2020-2023 | Rebyota |
| Redhill Biopharma INC. | $54.35 | 2021 | |
| Ardelyx, INC. | $51.66 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $36.04 | 2020-2021 | |
| Enterra Medical, INC. | $33.59 | 2022 | |
| Medtronic, INC. | $30.98 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.40 | 2022 | |
| Allergan, INC. | $15.64 | 2019 | |
| Shire North American Group INC | $14.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$36,705.67 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.